Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cabrera, Katrina
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
NCT05051722: Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer	Recruiting	2	2640	US	Tampon Collection, Vaginal Fluid, Blood Collection	Mayo Clinic	Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer	12/25	06/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma	Recruiting	1/2	390	US	ACR-368, prexasertib, Gemcitabine, OncoSignature	Acrivon Therapeutics, GOG Foundation	Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma	07/26	12/27